Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease von Doody, Rachelle S, Thomas, Ronald G, Farlow, Martin, Iwatsubo, Takeshi, Vellas, Bruno, Joffe, Steven, Kieburtz, Karl, Raman, Rema, Sun, Xiaoying, Aisen, Paul S, Siemers, Eric, Liu-Seifert, Hong, Mohs, Richard

Volltext

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease von Doody, Rachelle S, Raman, Rema, Farlow, Martin, Iwatsubo, Takeshi, Vellas, Bruno, Joffe, Steven, Kieburtz, Karl, He, Feng, Sun, Xiaoying, Thomas, Ronald G, Aisen, Paul S, Siemers, Eric, Sethuraman, Gopalan, Mohs, Richard

Volltext

Two Phase 3 Trials of Gantenerumab in Early Alzheimer’s Disease von Bateman, Randall J., Smith, Janice, Donohue, Michael C., Delmar, Paul, Abbas, Rachid, Salloway, Stephen, Wojtowicz, Jakub, Blennow, Kaj, Bittner, Tobias, Black, Sandra E., Klein, Gregory, Boada, Mercè, Grimmer, Timo, Tamaoka, Akira, Perry, Richard J., Turner, R. Scott, Watson, David, Woodward, Michael, Thanasopoulou, Angeliki, Lane, Christopher, Baudler, Monika, Fox, Nick C., Cummings, Jeffrey L., Fontoura, Paulo, Doody, Rachelle S.

Volltext

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease von Bateman, Randall J, Cummings, Jeffrey, Schobel, Scott, Salloway, Stephen, Vellas, Bruno, Boada, Mercè, Black, Sandra E, Blennow, Kaj, Fontoura, Paulo, Klein, Gregory, Assunção, Sheila Seleri, Smith, Janice, Doody, Rachelle S

Volltext

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial von Boxer, Adam L, Dr, Lang, Anthony E, Prof, Grossman, Murray, Prof, Knopman, David S, Prof, Miller, Bruce L, Prof, Schneider, Lon S, Prof, Doody, Rachelle S, Prof, Lees, Andrew, Prof, Golbe, Lawrence I, Prof, Williams, David R, MD, Corvol, Jean-Cristophe, MD, Ludolph, Albert, Prof, Burn, David, Prof, Lorenzl, Stefan, Prof, Litvan, Irene, Prof, Roberson, Erik D, MD, Höglinger, Günter U, Prof, Koestler, Mary, PhD, Jack, Clifford R, Prof, Van Deerlin, Viviana, MD, Randolph, Christopher, Prof, Lobach, Iryna V, PhD, Heuer, Hilary W, PhD, Gozes, Illana, Prof, Parker, Lesley, BSc, Whitaker, Steve, MD, Hirman, Joe, PhD, Stewart, Alistair J, PhD, Gold, Michael, MD, Morimoto, Bruce H, PhD

Volltext

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placeb... von Doody, Rachelle S, Prof, Gavrilova, Svetlana I, Prof, Sano, Mary, Prof, Thomas, Ronald G, Prof, Aisen, Paul S, Prof, Bachurin, Sergey O, Prof, Seely, Lynn, MD, Hung, David, MD

Volltext

Effectiveness of antidementia drugs in delaying Alzheimer's disease progression von Rountree, Susan D, Atri, Alireza, Lopez, Oscar L, Doody, Rachelle S

Volltext

Promoting diversity in clinical trials: insights from planning the ALUMNI AD study in historically underrepresented US populations with early symptomatic Alzheimer's disease von Wise-Brown, Alexandria, Brangman, Sharon A., Henderson, J. Neil, Willis-Parker, Monica, Monroe, Stephanie, Mintzer, Jacobo E., Grundman, Michael, Smith, Janice, Doody, Rachelle S., Lin, Helen, Assman, Beverly, Rippon, Gregory A., Gonzales, Rozanno, Assunção, Sheila Seleri

Volltext

Gantenerumab in Early Alzheimer's Disease. Reply von Bateman, Randall J, Smith, Janice, Doody, Rachelle S

Volltext

Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials von Ostrowitzki, Susanne, Bittner, Tobias, Sink, Kaycee M, Mackey, Howard, Rabe, Christina, Honig, Lawrence S, Cassetta, Emanuele, Woodward, Michael, Boada, Mercè, van Dyck, Christopher H, Grimmer, Timo, Selkoe, Dennis J, Schneider, Andres, Blondeau, Kathleen, Hu, Nan, Quartino, Angelica, Clayton, David, Dolton, Michael, Dang, Yifan, Ostaszewski, Beth, Sanabria-Bohórquez, Sandra M, Rabbia, Michael, Toth, Balazs, Eichenlaub, Udo, Smith, Jillian, Honigberg, Lee A, Doody, Rachelle S

Volltext

How Well Do the ADAS-cog and its Subscales Measure Cognitive Dysfunction in Alzheimer’s Disease? von Benge, Jared F., Balsis, Steve, Geraci, Lisa, Massman, Paul J., Doody, Rachelle S.

Volltext

The Dementia and Disability Project in Thai Elderly: rational, design, methodology and early results von Senanarong, Vorapun, Harnphadungkit, Kamolthip, Poungvarin, Niphon, Vannasaeng, Sathit, Chongwisal, Samut, Chakorn, Tipa, Jamjumrus, Piyanuch, Raksthaput, Atthapon, Chaichanettee, Sinisa, Aoonkaew, Nattapol, Udompunthurak, Suthipol, Doody, Rachelle S, Cummings, Jeffrey L

Volltext

Donepezil in Vascular Dementia: Combined Analysis of Two Large-Scale Clinical Trials von Román, Gustavo C., Wilkinson, David G., Doody, Rachelle S., Black, Sandra E., Salloway, Stephen P., Schindler, Rachel J.

Volltext

Development of a quantitative semi‐mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Q‐ATN model) von Mazer, Norman A., Hofmann, Carsten, Lott, Dominik, Gieschke, Ronald, Klein, Gregory, Boess, Frank, Grimm, Hans Peter, Kerchner, Geoffrey A., Baudler‐Klein, Monika, Smith, Janice, Doody, Rachelle S.

Volltext

Statistical Model of Dynamic Markers of the Alzheimer’s Pathological Cascade von Balsis, Steve, Geraci, Lisa, Benge, Jared, Lowe, Deborah A, Choudhury, Tabina K, Tirso, Robert, Doody, Rachelle S

Volltext

Predicting progression of Alzheimer's disease von Doody, Rachelle S, Pavlik, Valory, Massman, Paul, Rountree, Susan, Darby, Eveleen, Chan, Wenyaw

Volltext

Adding Delayed Recall to the ADAS-cog Improves Measurement Precision in Mild Alzheimer's Disease: Implications for Predicting Instrumental Activities of Daily Living von Lowe, Deborah A., Balsis, Steve, Benge, Jared F., Doody, Rachelle S.

Volltext

Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease von Rountree, Susan D, Chan, Wenyaw, Pavlik, Valory N, Darby, Eveleen J, Siddiqui, Samina, Doody, Rachelle S

Volltext

Validation of olfactory deficit as a biomarker of Alzheimer disease von Woodward, Matthew R, Amrutkar, Chaitanya V, Shah, Harshit C, Benedict, Ralph H B, Rajakrishnan, Sanjanaa, Doody, Rachelle S, Yan, Li, Szigeti, Kinga

Volltext

PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury von Hammond, Flora M, Alexander, David N, Cutler, Andrew J, D'Amico, Stephen, Doody, Rachelle S, Sauve, William, Zorowitz, Richard D, Davis, Charles S, Shin, Paul, Ledon, Fred, Yonan, Charles, Formella, Andrea E, Siffert, Joao

Volltext